---
title: "INFU: Record revenue and margin gains fueled by Oncology and wound care growth, with positive outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294840749.md"
description: "Record quarterly revenue and margin expansion were driven by strong Oncology and wound care growth, with significant margin improvement from the GE HealthCare contract restructuring. Outlook remains positive, with continued growth expected in core segments and stable EBITDA margins.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-04T14:31:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294840749.md)
  - [en](https://longbridge.com/en/news/294840749.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294840749.md)
---

# INFU: Record revenue and margin gains fueled by Oncology and wound care growth, with positive outlook

Record quarterly revenue and margin expansion were driven by strong Oncology and wound care growth, with significant margin improvement from the GE HealthCare contract restructuring. Outlook remains positive, with continued growth expected in core segments and stable EBITDA margins.

Based on

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [INFU.US](https://longbridge.com/en/quote/INFU.US.md)
- [GEHC.US](https://longbridge.com/en/quote/GEHC.US.md)

## Related News & Research

- [INFU: Q2 2026 revenue grew 2.6% to $36.9M, with higher margins and reaffirmed full-year guidance](https://longbridge.com/en/news/294810490.md)
- [InfuSystem publishes investor presentation on home healthcare platform for complex therapies outside hospitals](https://longbridge.com/en/news/294825628.md)
- [AI prices are plunging. That feels bad, but something else is happening.](https://longbridge.com/en/news/295909356.md)
- [CNSP: Strategic pivot targets high-value oncology and neurology assets with strong financial backing](https://longbridge.com/en/news/296126240.md)
- [How Investors May Respond To Labcorp (LH) Expanding PTEN Dx Reach Amid Oncology Leadership Transition](https://longbridge.com/en/news/296154982.md)